Ubs Group Ag Imara Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$3.73 - $5.2 $10,611 - $14,794	2,845 New	2,845 $11,000
Q1 2022 May 16, 2022	SELL	$1.15 - $2.41 $5,157 - $10,808	-4,485 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.25 - $4.05 $10,091 - $18,164	4,485 New	4,485 $10,000
Q3 2021 Nov 15, 2021	SELL	$4.08 - $7.83 $8,743 - $16,779	-2,143 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$6.78 - $9.04 $3,417 - $4,556	504 Added 30.75%	2,143 $17,000
Q1 2021 May 12, 2021	BUY	$8.18 - $23.98 $4,278 - $12,541	523 Added 46.86%	1,639 $14,000
Q4 2020 Feb 11, 2021	BUY	$15.81 - $29.0 $17,643 - $32,364	1,116 New	1,116 $25,000
Q3 2020 Nov 12, 2020	SELL	$18.75 - $28.58 $29,287 - $44,641	-1,562 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$15.6 - $54.87 $24,367 - $85,706	1,562 New	1,562 $43,000

104K

170K

Ticker IMRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,287,300
Market Cap $552M
Description
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develop...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.